Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage IIIB Prostate Cancer AJCC v8: early-phase trial registry
7 of 11 indexed Stage IIIB Prostate Cancer AJCC v8 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · 7 currently recruiting · #1,577 of 28,707 conditions by registered trial count
Stage IIIB Prostate Cancer AJCC v8: 11 US clinical trials tracked, 7 recruiting.
Stage IIIB Prostate Cancer AJCC v8 is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Jonsson Comprehensive Cancer Center, running 2 of these trials.
Enrollment posture brief
Registry condition stage-iiib-prostate-cancer-ajcc-v8
OPEN 7 | RECR 64% | LATE 0 | EARLY 6 | RANK #1577 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Advanced Melanoma (64% recruiting · 22 trials)
Stage IIIB Prostate Cancer AJCC v8 lists 7 open slots (64% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage IIIB Prostate Cancer AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage IIIB Prostate Cancer AJCC v8 is recruiting above its size-band peers.
7 of 11 indexed trials (63.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Stage IIIB Prostate Cancer AJCC v8 research.
Jonsson Comprehensive Cancer Center accounts for 2 of 11 trials (18.2%). 8 distinct sponsors appear on at least one study for this condition label.
-
Most Stage IIIB Prostate Cancer AJCC v8 trials plan to enrol fewer than 100 people.
Median target enrolment is 52 among the 11 trials that report a genuine target (sentinel values excluded). 9 of those (81.8%) plan for fewer than 100 participants.
-
Stage IIIB Prostate Cancer AJCC v8 research is mostly interventional.
10 interventional and 1 observational studies make up this index (90.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
11 total, page 1 of 1
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
NCT04947254
Focal Ablation With Focal Cryotherapy or HIFU for the Treatment of Men With Localized Prostate Cancer
Marc Dall'Era, MD
NCT06178354
Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial
Jonsson Comprehensive Cancer Center
NCT06067269
High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma
Jonsson Comprehensive Cancer Center
NCT04945642
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
SWOG Cancer Research Network
NCT05806515
Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer
Emory University
NCT04725903
Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND Network
Thomas Jefferson University
NCT05627219
RElugolix VErsus LeUprolide Cardiac Trial
Emory University
NCT05320406
Watchful Living in Improving Quality of Life in Participants With Localized Prostate Cancer on Active Surveillance and Their Partners
M.D. Anderson Cancer Center
NCT03575832
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
Roswell Park Cancer Institute
NCT03899987
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
NCT04037254
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage IIIB Prostate Cancer AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage IIIB Prostate Cancer AJCC v8 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage IIIB Prostate Cancer AJCC v8 page
11 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Stage IIIB Prostate Cancer AJCC v8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Jonsson Comprehensive Cancer Center sponsors the most Stage IIIB Prostate Cancer AJCC v8 trials on record, review their full trial history before evaluating a specific study. See Jonsson Comprehensive Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage IIIB Prostate Cancer AJCC v8 condition card totals 11 registered trials; most-linked intervention High-Dose Rate Brachytherapy; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.